If you have never heard of Spravato, you are in the large majority. In our commissioned survey, 73 percent of 443 Midwest adults drew a blank on the name, 21 percent recognized it without more, and a slim 6 percent could explain the treatment.
This explainer is meant for readers who carry employer-sponsored or other commercial health insurance who want to understand what Spravato is and how it tends to work with the kind of plan they have. It does not tell you whether the treatment is right for you. That is a question for your clinician. It aims to make the conversation easier.
The basics
Spravato delivers esketamine through the nose, and its approval from the FDA is for adults with treatment-resistant depression, a label clinicians usually apply once two or more antidepressants, each tried properly, have left major depression largely in place. Patients typically take it alongside an oral antidepressant.
It works differently from most common antidepressants, which is part of why it is considered for people who have not responded to them.
How treatment happens
You will not collect Spravato from a pharmacy counter for home use. Federal safety rules under a REMS program limit it to certified healthcare settings.
- You self-administer the spray while a healthcare provider watches.
- You stay at the center for monitoring afterward, because the drug can cause sedation, dissociation, and blood pressure changes.
- Driving and operating machinery are off the table until the next day, after a night of sleep, so plan a ride home.
- The early phase involves more frequent visits, which usually taper later.
For many people, the logistics are the biggest practical hurdle. In our survey, closeness to home was among the two biggest provider factors for 43 percent.
How it is different from at-home ketamine
Some telehealth companies prescribe ketamine for use at home. Ketamine is a related but different drug that lacks FDA approval for depression, which makes that use off-label. It is often cash-pay and involves far less supervision. When reading about "ketamine therapy," check which one is being described. An overview of Spravato treatment covers the approved option in more detail.
How commercial plans usually handle it
Every plan is different, but a few patterns are common.
Prior authorization. Most plans that cover Spravato require your doctor or treatment center to request approval first. The insurer typically wants documentation that you have tried other antidepressants without enough improvement.
Medical or pharmacy benefit. Depending on the plan and the treatment center, Spravato may be billed under your medical benefit, with the center buying the drug and billing the insurer, or under your pharmacy benefit through a specialty pharmacy. Which one applies can change your cost sharing, so ask.
Network. The certified treatment center needs to be in your plan's network, or you may face much higher costs. Not every certified center accepts every plan.
Cost sharing. Your deductible, copays, and coinsurance all apply. Because early treatment involves more visits, costs can be front-loaded, especially early in the plan year before you meet your deductible.
Monitoring visits. The observation time and office visit may be billed separately from the drug itself.
Why coverage is worth pursuing
Our survey found that coverage is the single most important factor in how people choose a provider. It was a top-two priority for 85 percent. Offered covered care with more hoops or a simpler self-pay route, a slim majority chose coverage, while 23 percent preferred to pay and 26 percent were unsure. Of the 173 respondents on commercial plans, 50 percent made that same covered-with-hoops choice.
For someone with commercial insurance, the hoops are usually paperwork. Knowing them in advance makes them less discouraging.
A few terms, decoded
- Prior authorization: Your insurer's approval before treatment begins.
- Step therapy: A requirement to try other treatments first. For Spravato, this usually means documented antidepressant trials.
- Specialty pharmacy: A pharmacy that handles drugs needing special handling or oversight, sometimes used to deliver Spravato to the treatment center.
- Buy-and-bill: When the treatment center purchases the drug and bills your insurer under the medical benefit.
- Out-of-pocket maximum: The most you pay in a plan year for covered in-network care. Ask where you stand against it.
If you get denied
A first denial is common and often not the last word. Your doctor can submit more information or ask for a doctor-to-doctor talk with the insurer's reviewer. You also have the right to a formal internal appeal and, in many cases, an independent external review. If your plan is through a large employer, your HR benefits team may also be able to help you understand the process.
Who to talk to first
Start with your doctor, the same first move most respondents would make: 56 percent would begin with primary care, and for 74 percent, their own doctor's recommendation carries the most weight in trying something new. In the commercially insured group, that pull was stronger still, at 81 percent. Take along your antidepressant history and ask plainly whether esketamine belongs in the conversation.
Next, phone your insurer using the number on the card. Find out if Spravato is covered, what the prior authorization criteria say, which benefit it falls under, medical or pharmacy, and which certified centers nearby are in network.
A reminder about safety
Esketamine is not appropriate for everyone. Certain blood vessel conditions, a past brain bleed of some kinds, and other health factors can rule people out. Your clinician will review this with you.
And if at any point you are thinking about ending your life, set the paperwork aside. Reach out at 988, by call or text. Whatever the hour and whatever your insurance, trained staff pick up for the Suicide and Crisis Lifeline; the service keeps what you say private, charges nothing, and lets veterans press 1.
Methodology
Our numbers come from a Pollfish consumer panel study that 443 adults aged 18 to 64 completed, from Oklahoma, Missouri, Ohio, Illinois, Kansas, Nebraska, Wisconsin, Iowa, Indiana, and Minnesota; the survey stopped taking answers on June 23, 2026. Results are whole-sample figures except the commercial-plan breakdown noted above, and all come from Pollfish's final validated data. Our publisher ordered the research and funded it. Plan rules vary; confirm details with your insurer. This is not medical advice.